Weekly Digest - December 2024

Weekly Digest - December 2024

16 Dec 2024: Biocytogen announces Adcendo ApS exercises antibody option to accelerate ADC development

  • Biocytogen Pharmaceuticals announced that Adcendo ApS has exercised its option under a research, option, and license agreement to use Biocytogen’s fully human antibodies to expand its ADC pipeline

  • Biocytogen’s RenMice® platform is being leveraged in this collaboration to discover fully human antibodies with high affinity, low immunogenicity, and favorable developability

  • The collaboration aims to support Adcendo’s development of innovative ADC drug candidates for the treatment of cancers with high unmet medical need

  • Biocytogen, expressed confidence that the collaboration would drive the rapid advancement of novel therapies for global patients

For full story click here

Share this